Sallyann Vu
0009-0008-6252-4439
Publication & Citation Trends
Publications
0 total
Abstract 1619: Discovery and optimization of XTX601, a masked claudin 18.2-targeting T cell engager
Cited by 0
Semantic Scholar
972 Masked T cell engagers designed to drive potent synthetic anti-tumor immunity with favorable tolerability
Cited by 0
Semantic Scholar
Abstract 719: A tumor-activated PD1/IL2 bispecific molecule, designed to overcome IL-2 receptor-mediated clearance, improve tolerability and stimulate antigen-experienced CD8+ T cells in the tumor microenvironment of murine models
Cited by 0
Semantic Scholar
1296 Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models OA
Cited by 0
Semantic Scholar
Abstract 572: Tumor-activated PD1-directed IL-2 increased antigen specific T cells in tumors and demonstrated anti-tumor activity in mice
Cited by 1
Semantic Scholar
Abstract 587: A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models
Cited by 0
Semantic Scholar
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies OA
Cited by 7
Semantic Scholar
1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models OA
Cited by 0
Semantic Scholar
Research Topics
Cytokine Signaling Pathways and Interactions
(44)
Cancer Immunotherapy and Biomarkers
(7)
Immunotherapy and Immune Responses
(7)
Monoclonal and Polyclonal Antibodies Research
(7)
Virus-based gene therapy research
(6)
Affiliations
Xilio Therapeutics (United States)